Literature DB >> 30851216

Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease.

Elena Buzzetti1,2, Salvatore Petta3, Roberta Manuguerra4, Tu Vinh Luong4, Daniela Cabibi5, Elena Corradini1, Antonio Craxì3, Massimo Pinzani2, Emmanuel Tsochatzis2, Antonello Pietrangelo1.   

Abstract

BACKGROUND & AIMS: Hyperferritinemia, with or without increased hepatic iron, represents a common finding in non-alcoholic fatty liver disease (NAFLD). However, it is unclear whether it reflects hepatic inflammation or true iron-overload and, in case the latter is confirmed, whether this influences disease progression. We therefore explored the association between serum ferritin, degree and pattern of hepatic iron deposition and liver disease severity in patients with NAFLD.
METHODS: We selected 468 patients with biopsy-proven NAFLD from 2 European centres. Iron, hepatic and metabolic parameters were collected at the time of liver biopsy. Iron deposits in hepatocytes and reticuloendothelial cells were assessed and graded. Diagnosis of non-alcoholic steatohepatitis (NASH) and fibrosis staging were performed.
RESULTS: A total of 122 (26%) patients had hyperferritinemia, whereas stainable hepatic iron was found in 116 (25%) patients (38% predominantly in hepatocytes, 20% in reticuloendothelial cells and 42% in both). Subjects with stainable hepatic iron, particularly those with a mixed pattern, had higher serum ferritin and transaminases but only a mixed pattern of iron deposition was among the variables significantly associated with presence of NASH. Serum ferritin was not associated with presence of NASH, however it increased with worsening fibrosis stage (F3 compared to F0-F1), and significantly decreased in stage F4.
CONCLUSIONS: A mixed pattern of hepatic iron deposition is associated with the presence of steatohepatitis, while serum ferritin increases with worsening fibrosis up to pre-cirrhotic stage. In individual NAFLD patients, serum ferritin could be evaluated as part of non-invasive diagnostic panels but not on its own.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ferritin; histology; iron; non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2019        PMID: 30851216     DOI: 10.1111/liv.14096

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

2.  Is intervertebral disc degeneration associated with reduction in serum ferritin?

Authors:  Youfeng Guo; Chao Li; Beiduo Shen; Xianzhen Chen; Tao Hu; Desheng Wu
Journal:  Eur Spine J       Date:  2022-08-25       Impact factor: 2.721

3.  Radiomics nomograms based on R2* mapping and clinical biomarkers for staging of liver fibrosis in patients with chronic hepatitis B: a single-center retrospective study.

Authors:  Die Zhang; Yi Cao; Yi Sun; Xia Zhao; Cheng Peng; Jing Zhao; Xiaohui Bao; Lifei Wang; Chen Zhang
Journal:  Eur Radiol       Date:  2022-09-23       Impact factor: 7.034

4.  Nonalcoholic Steatohepatitis Modifies Serum Iron-Related Variables in Patients with Morbid Obesity.

Authors:  Anna Hernández-Aguilera; Núria Casacuberta; Helena Castañé; Montserrat Fibla; Salvador Fernández-Arroyo; Isabel Fort-Gallifa; Marta París; Fàtima Sabench; Daniel Del Castillo; Gerard Baiges-Gaya; Elisabet Rodríguez-Tomàs; Teresa Sans; Jordi Camps; Jorge Joven
Journal:  Biol Trace Elem Res       Date:  2021-02-08       Impact factor: 3.738

Review 5.  Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets.

Authors:  Long-Xia Li; Fang-Fang Guo; Hong Liu; Tao Zeng
Journal:  Cell Mol Life Sci       Date:  2022-03-24       Impact factor: 9.261

Review 6.  Therapeutic potential of induced iron depletion using iron chelators in Covid-19.

Authors:  Punnoth Poonkuzhi Naseef; Muhammed Elayadeth-Meethal; K T Mohammed Salim; A Anjana; C Muhas; K Abdul Vajid; Mohamed Saheer Kuruniyan
Journal:  Saudi J Biol Sci       Date:  2021-12-13       Impact factor: 4.052

7.  The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults.

Authors:  Naibin Yang; Yi Lu; Liwen Cao; Mingqin Lu
Journal:  J Clin Lab Anal       Date:  2022-01-07       Impact factor: 2.352

8.  Association between Different Animal Protein Sources and Liver Status in Obese Subjects with Non-Alcoholic Fatty Liver Disease: Fatty Liver in Obesity (FLiO) Study.

Authors:  Gregorio Recaredo; Bertha Araceli Marin-Alejandre; Irene Cantero; J Ignacio Monreal; José Ignacio Herrero; Alberto Benito-Boillos; Mariana Elorz; Josep A Tur; J Alfredo Martínez; M Angeles Zulet; Itziar Abete
Journal:  Nutrients       Date:  2019-10-03       Impact factor: 5.717

9.  Mesenchymal iron deposition is associated with adverse long-term outcome in non-alcoholic fatty liver disease.

Authors:  Sebastian K Eder; Alexandra Feldman; Georg Strebinger; Jana Kemnitz; Stephan Zandanell; David Niederseer; Michael Strasser; Heike Haufe; Karl Sotlar; Felix Stickel; Bernhard Paulweber; Christian Datz; Elmar Aigner
Journal:  Liver Int       Date:  2020-05-28       Impact factor: 5.828

10.  The Relationship of Hyperferritinemia to Metabolism and Chronic Complications in Type 2 Diabetes.

Authors:  Xiaojing Shang; Rui Zhang; Xiaolai Wang; Junxin Yao; Xiaoying Zhao; Huanming Li
Journal:  Diabetes Metab Syndr Obes       Date:  2022-01-15       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.